President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
The meeting comes amid months of stalled trade talks between Washington and New Delhi, resulting in both sides taking retaliatory measures.Asia Politicsread more
Gas prices could rise by about 20 cents per gallon "starting tomorrow," oil analyst Andy Lipow says Monday.Oil and Gasread more
shortage@ (Adds background on Pfizer manufacturing issues)
July 9 (Reuters) - Novartis AG said on Tuesday it would make its generic pre-filled epinephrine shots immediately available in local pharmacies across the United States, as a shortage of Mylan NV's EpiPen emergency allergy treatment drags on due to manufacturing problems.
Novartis' Sandoz unit launched the Symjepi epinephrine shots for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner.
The Swiss drugmaker has an exclusive agreement with Adamis Pharmaceuticals Corp to distribute and commercialize Symjepi in the United States.
Novartis said both the adult and pediatric doses of Symjepi would be immediately available in local U.S. pharmacies.
The wholesale price for a two-pack of adult-dose syringes is $250, Novartis said, below the $300 charged by Mylan for its authorized generic and for Teva's generic version of the EpiPen auto-injector.
Mylan still dominates the market for emergency allergy shots with its EpiPen that delivers a dose of epinephrine in the event of severe, potentially life-threatening allergic reactions to a number of triggers, such as bee stings or peanuts.
But there has been a shortage of EpiPens in the United States, Europe and Canada due to manufacturing delays. The U.S. Food and Drug Administration added the treatment to its list of drugs in shortage more than a year ago, and it remains on that list.
Pfizer Inc's Meridian Medical unit, which produces all EpiPens sold globally at a single plant near St. Louis, has been hit by a series of manufacturing problems. The company said in a statement on Tuesday that it anticipates further supply shortages over the coming months.
There is traditionally high demand for the devices in the summer as families look to renew prescriptions ahead of sending children to summer camp or the new school year.
Teva has built significant market share with its generic this year, reaching 18% of the market in late June, according to a research note from Leerink that cited IQVIA prescription volume data.
Teva said in May it expected to reach around 20% market share by the end of the second quarter and could approach 50% market share by the end of the year. (Reporting by Aakash Jagadeesh Babu and Tamara Mathias in Bengaluru and Michael Erman in New York; Editing by Maju Samuel and Bill Berkrot)